193 results about "Ischemia" patented technology

The invention provides an intravascular occluder which comprises an occluder body, a catheter part and a control mechanism, the occluder body is of an umbrella-shaped structure formed by a plurality of frameworks which can be opened, and a layer of covering is attached to the occluder body; the catheter part is used for accommodating the plugging device and the connecting rod part of the control mechanism; the control mechanism comprises a connecting rod part and a handle control part, and is used for controlling the pushing and withdrawing of the plugging device; after the plugging device is unfolded to completely plug the inner diameter of the blood vessel, the function of cutting off blood flowing can be achieved, a space for blood flowing can be reserved at the position close to the inner wall of the blood vessel by properly retracting the plugging device into the catheter, and the plugging device can be completely retracted into the catheter by completely retracting the plugging device. The device has the advantages that unfolding and folding are completely reversible, controllable opening and cutting of blood flow can be achieved, complications caused by long-time ischemia of blocked blood vessels can be avoided, and a long-time operation becomes possible.

The invention discloses a man-machine suitability evaluation method for a mattress, and relates to the field of human engineering health monitoring, and the method comprises the steps: screening testers according to a BMI grading standard, and collecting the height, weight, gender, age, sleep habit and chronic pain medical history basic data of the testers to obtain the BMI values of the testers; inputting the BMI value of the tester into the mattress hardness selection model to obtain the hardness range of the tested mattress, arranging a to-be-tested mattress with selected hardness in a constant-temperature and constant-humidity experimental environment, and enabling the tester to lie on the to-be-tested mattress in sequence at a standard supine position and a standard lateral position. According to the method, the spine stiffness demand curve is predicted in real time through the LSTM neural network, millisecond-level dynamic support adjustment is achieved, the response speed is remarkably increased compared with a traditional method, and spine compensatory bending in sleep can be prevented; and in combination with pressure-blood oxygen coupled IRI index calculation, microcirculation disturbance is accurately warned before tissue injury, and the problem of local ischemia is solved through partition adjustment.

The invention discloses a local oxygen therapy, flushing and skin stretching device for chronic wound treatment, and relates to the technical field of medical apparatuses and instruments, the local oxygen therapy, flushing and skin stretching device comprises a stretching disc, and a cleaning device is arranged in the middle of the stretching disc; according to the device, breakthrough is achieved through the combination of the circular structure of the stretching disc and the circumferentially-distributed T-shaped sliding racks; the circular geometric structure of the stretching disc has stress symmetry, and stretching force can be evenly dispersed; the position of the T-shaped sliding rack installed in a circumferential sliding mode can be flexibly adjusted in the radial direction of the stretching disc, and six or more stretching points can be set at will according to the boundary of the wound surface in cooperation with the sliding block and the T-shaped hook frame which can slide. For example, for an irregular polygonal wound surface of a diabetic foot, a medical worker can mark six stress balance points on the T-shaped sliding rack and fix the hook, synchronous or independent adjustment of multiple distraction points is achieved through linkage of the rotating gear ring and the multiple sets of gears, and the situation that skin ischemia blister is caused by too large local stress or tissue stretching is affected by insufficient stress is avoided.

The invention relates to the technical field of intraoperative intelligent monitoring, and particularly discloses a spinal canal debonding method and system for real-time state evaluation, and the method comprises the steps: collecting neural structure microcirculation blood flow data in real time through integrating a micro-sensing unit at a working end part of a surgical instrument, and extracting blood flow oscillation frequency and capillary hematocrit parameters; performing multi-scale signal decomposition on the blood flow oscillation frequency to obtain an energy distribution parameter, and performing dynamic mode recognition on the hematocrit data to obtain a main variation characteristic value; fusing the two characteristic parameters to generate a nervous tissue vitality index; inputting the index into a pre-trained neural network for time sequence feature analysis, and outputting a graded ischemia risk early warning signal; the operation rhythm is automatically adjusted through a decision tree control mechanism based on the early warning signal, and self-adaptive regulation and control according to the state of the nervous tissue are achieved; the technical problem that the risk of neural ischemia cannot be monitored in real time in a traditional spinal canal release operation is solved, and occult nerve injury caused by asymptomatic neural ischemia can be prevented.

The invention provides a lipoic acid-based nano-enzyme and a preparation method and application thereof, firstly, lipoic acid is dissolved in an organic solvent by utilizing the amphipathy of the lipoic acid and is self-assembled in water to form a nano-aggregate, and then ring opening polymerization of the lipoic acid is initiated by ultraviolet irradiation to obtain stable lipoic acid nano-particles, namely the lipoic acid-based nano-enzyme. The lipoic acid-based nano-enzyme has the beneficial effects that the preparation method of the lipoic acid-based nano-enzyme prepared by the method is simple, the lipoic acid-based nano-enzyme has stable particle size, good active oxygen scavenging ability and blood brain barrier crossing ability, and in addition, a cavity in the nano-enzyme is suitable for loading hydrophobic bioactive factors and drugs, so that the lipoic acid-based nano-enzyme has a good application prospect. Rich carboxyl groups on the surface of the nano-enzyme can be complexed with various ions, and the nano-enzyme can be applied to treatment of inflammation diseases caused by hypoxia or ischemia and the like and brain drug delivery.

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.

The invention discloses an electrocardio data processing and coronary heart disease risk prediction method, device and system and a medium. The method comprises the steps of obtaining exercise electrocardio data output through at least one electrocardiogram lead; analyzing the exercise electrocardiogram data to obtain a heart rate sequence corresponding to each electrocardiogram lead; extracting a QRS wave group corresponding to each heart beat from the exercise electrocardio data; dividing a plurality of heart rate intervals according to the obtained heart rate sequence; according to the heart rate interval to which the heart rate corresponding to each QRS wave group belongs, classifying the QRS wave group into a group corresponding to the corresponding heart rate interval; determining an average QRS wave group corresponding to each heart rate interval according to all the QRS wave groups in each group; extracting the high-frequency energy of the average QRS wave group corresponding to each heart rate interval; and determining an energy sequence according to the high-frequency energy corresponding to each heart rate interval. According to the scheme, high-frequency components and dynamic load information which are more sensitive to ischemia are utilized, so that the detection rate and the identification capability of coronary heart diseases, particularly early and mild lesions, can be remarkably improved.

The flow-adjustable perfusion balloon catheter comprises a catheter body, a balloon capable of being filled and a catheter base, a push rod channel and a filling channel are arranged in the catheter body, the filling channel is communicated with an inner cavity of the balloon, and a first connector and a second connector are arranged on the catheter base. Micropores are formed in the positions, located at the near end and the far end of the balloon, of the catheter body and are the near-end micropore and the far-end micropore respectively, the near-end micropore and the far-end micropore are communicated through a blood flow channel formed in the catheter body, and a blocking piece capable of blocking the near-end micropore or the far-end micropore is arranged in the blood flow channel. A push rod is arranged in the push rod channel, and the far end of the push rod is connected with the near end of the plugging piece. Compared with the prior art, by arranging the blood flow channel, effective circulation of blood flow can still be achieved after balloon plugging in the operation, complications caused by ischemia or hypertension in the operation are avoided, the perfusion blood flow can be adjusted in time according to different patient conditions, and the success rate of the operation is increased.

The present invention relates to an injectable pre-formulation comprising:a) at least one of a mono-, di- or tri-acyl lipid and / or a tocopherol;b) optionally at least one phospholipid;c) at least one biocompatible, organic solvent; andd) at least one prostacyclin analogue or a salt thereof;wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. Such compositions may additionally comprise polar co-solvents. Methods of treatment, particularly for management of pulmonary artery hypertension (PAH), severe PAH, Raynaud's disease, ischemia and related conditions are provided, as well as corresponding uses of the compositions. Administration devices comprising the formulations and kits comprising the devices are also provided.

The utility model relates to medical instrument technical field especially is a kind of wearable femoral vein compression hemostasis device, including disposable underpants body, the upper surface of one side of trouser leg is located at femoral vein and is fixedly installed with the compression assembly for fixing wound, and the compression assembly includes clamping ring plate, the middle part of clamping ring plate is equipped with four groups of insertion slot, the surface both sides of waistband are fixedly installed with trouser loop, and the periphery of waistband is provided with the bandage assembly for exerting pressure and is set, and the bandage assembly includes waist bandage and leg bandage, the both ends of waist bandage are insertedly installed in the inside of insertion slot, the both ends of leg bandage are also insertedly installed in the inside of insertion slot, the both ends of waist bandage can be folded and detachably connected, and the both ends of leg bandage can be folded and detachably connected.The utility model is folded and detachably connected by underpants design, bandage, clamping ring plate disperses pressure, reduces the risk of local ischemia, and waist bandage and leg bandage synergistic effect, form three-dimensional compression.

A method, device, system and medium for electrocardio data processing and coronary heart disease risk prediction, motion electrocardio data output through at least one electrocardio lead is acquired; the motion electrocardio data is analyzed to obtain a heart rate sequence corresponding to each electrocardio lead; each QRS complex corresponding to each heartbeat is extracted from the motion electrocardio data; a plurality of heart rate intervals are divided according to the obtained heart rate sequence; each QRS complex is classified into a group corresponding to a heart rate interval according to the heart rate interval to which the heart rate corresponding to the QRS complex belongs; the average QRS complex corresponding to each heart rate interval is determined according to all QRS complexes in each group; the high-frequency energy of the average QRS complex corresponding to each heart rate interval is extracted; and an energy sequence is determined according to the high-frequency energy corresponding to each heart rate interval. The present scheme uses high-frequency components and dynamic load information which are more sensitive to ischemia, and can significantly improve the detection rate and discrimination ability for coronary heart disease, especially early and mild lesions.

The invention discloses a GLP-1 (32-36) engineered exosome and application of the GLP-1 (32-36) engineered exosome in drugs and instruments for preventing and / or treating diabetic lower limb arterial lesion. The preparation process and related characteristics of the GLP-1 (32-36) engineered exosome are respectively as shown in figures (1) and (2). The exosome is prepared by treating human pluripotent stem cells by using GLP-1 (32-36). The GLP-1 (32-36) engineered exosome has relatively high activity in plasma, and the enterotrypsin synthetic peptide can effectively improve the yield of the exosome and further optimize the function of the exosome, so that a stronger therapeutic effect of promoting angiogenesis after ischemia is exerted. The GLP-1 (32-36) engineered exosome disclosed by the invention also has safety and can be used for a treatment strategy of diabetic lower limb artery complications.

The invention discloses a pressure monitoring device and method for evaluating pressure sore risk, and relates to the technical field of medical equipment. The system comprises a pressure sensing unit used for collecting pressure distribution data between the body surface of a patient and a supporting surface; the distance measuring device is used for measuring the distance between the device and the body surface of the patient. According to the method, information of three different dimensions of pressure distribution, body surface image and deep thermal imaging is subjected to fusion analysis, a pressure sensor positions a high-risk pressed area, a high-definition color image is used for identifying macroscopic skin damage and color change, infrared thermal imaging can penetrate through a surface layer, and the image can be used for identifying the skin damage and color change. According to the method, deep tissue temperature abnormity caused by ischemia and inflammation is sensitively captured, and the three types of information are integrated into a quantitative comprehensive risk score through a weighting algorithm, so that an evaluation result does not depend on subjective experience of nursing personnel any more and is converted into objective and quantifiable accurate diagnosis, and the screening accuracy of high-risk patients is remarkably improved.

The present disclosure relates to a method for reducing or hindering development of renal ischemia-reperfusion injury in a subject the method comprising administering an antibody that inhibits granulocyte colony stimulating factor (G-CSF) signaling. In some examples, the ischemia-reperfusion injury is due to or associated with tissue or organ transplantation.

The invention belongs to the technical field of medicines, and particularly relates to application of penicillin tenuipes in preparation of a product for preventing or treating ischemic encephalopathy, cell experiments and animal experiments show that penicillin tenuipes has a good treatment effect on cerebral thrombosis and middle artery embolism, can obviously improve behavioral scores after ischemia, and can be used for preparing a medicine for preventing or treating ischemic encephalopathy. And cerebral thrombus and blood vessel diameter conditions. The penicillin tenuipes also has an anti-inflammatory effect. Therefore, the compound can be used for preparing medicines for preventing or treating ischemic encephalopathy.

The invention relates to the technical field of hemostasis, and discloses a medical wrist strap with a hemostasis function, which comprises a main body assembly, a wrist strap body and a locking assembly, an information nameplate is fixed on one side of the wrist strap body, the wrist strap body is made of an elastic bandage, the locking assembly is arranged on the wrist strap body and comprises a rotating part, and the rotating part comprises a fixed frame. The wrist strap has the beneficial effects that the wrist strap is made of an elastic bandage material and is matched with the locking assembly, when hemostasis is needed in emergency, hemostasis can be carried out on the bleeding part of a patient through the wrist strap, the length of the wrist strap can be adjusted, the wrist strap can be bound to different bleeding parts of the patient, and after hemostasis is carried out for a certain period of time, the wrist strap can be fixed. In addition, the wrist strap can be automatically relaxed for a short time and tightened again, so that blood circulation of the far end of the limb can be temporarily recovered, and serious injury, such as muscle necrosis, nerve injury and the like, of limb tissue caused by long-time ischemia is avoided.

The invention relates to the technical field of gynecological medical instruments, and discloses an intelligent vagina support system, which comprises a shape memory alloy support skeleton, which comprises a memory alloy skeleton and a connecting ring, the phase change temperature of the shape memory alloy support skeleton is set to be in a human body vagina temperature range, and the shape memory alloy support skeleton is subjected to phase change under temperature triggering and dynamically adapts to pelvic floor muscle stress change; the detachable double-channel medicine bin comprises a detachable antibiotic medicine bin and a detachable estrogen medicine bin which are respectively and correspondingly used for treating infection and vaginal atrophy; and the sensing module comprises an outer insulating layer, an inner electrode and a main body, integrates a pressure sensor and a pH detection electrode, and is used for monitoring environmental parameters in the vagina in real time. The system adopts shape memory alloy as a supporting framework, austenite phase change occurs under triggering of body temperature, and the system is dynamically attached to the anatomical structure of the vagina. Stable radial supporting force is provided during resting and is lower than a mucous membrane ischemia threshold value; when the abdominal pressure suddenly rises during cough or movement, dynamic supporting force compensation is provided through hyperelastic deformation, and instrument displacement or compression injury is effectively prevented.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of a transcription factor ZHX2 in diagnosis and treatment of hepatic ischemia-reperfusion injury. Specifically, research finds that the expression of ZHX2 after ischemia reperfusion injury is reduced, and HIRI cell necrosis and generation and development of HIRI are obviously promoted by specifically knocking out Zhx2 from liver cells, which are further proved in marginal liver IRI, while the ZHX2 has a protective effect on marginal fatty liver ischemia reperfusion injury. In conclusion, the ZHX2 can be used as a biological marker and a related treatment target of the hepatic ischemia reperfusion injury, especially marginal hepatic ischemia reperfusion injury, so that the ZHX2 has good clinical application value and social benefit.

Liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using the provided trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

The invention relates to the technical field of medicines, in particular to application of mulberry bark extract in preparation of medicines for preventing and / or treating ischemia-reperfusion injury, and finds that morusin administration treatment can effectively relieve pathological injury of mouse liver tissue, reduce activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum after hepatic ischemia-reperfusion, and can be used for preparing medicines for preventing and / or treating ischemia-reperfusion injury. The expression of inflammatory cytokines is inhibited, and the proportion of apoptotic cells is remarkably reduced. The invention further finds that the morusin inhibits the expression of 15-hydroxyeicosapentaenoic acid (15-HETE), and the protection effect of the morusin on the HIRI can be reversed by adding the 15-HETE, so that the morusin can be used for inhibiting the expression of the 15-hydroxyeicosapentaenoic acid (15-HETE).

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

The invention discloses application of a BTK inhibitor in preparation of a medicine for treating acute kidney injury and complications thereof. The invention provides a new strategy for treating acute kidney injury and complications thereof by using a BTK inhibitor, and particularly relates to application of the BTK inhibitor as an acute kidney injury medicine. The invention finds that serum creatinine and urea nitrogen levels can be effectively reduced by knocking out mouse BTK, and kidney injury is relieved and conversion from AKI to CKD is delayed or prevented by recovering kidney pathological structure and reducing apoptotic cell generation, which indicates that BTK is an effective target for treating acute kidney injury. Meanwhile, through treatment of an acute renal ischemia-reperfusion model, it is found that the BTK inhibitor such as ibrutinib can relieve ischemia-reperfusion induced renal function impairment and improve the renal function of a mouse, and it is indicated that the BTK inhibitor can serve as a treatment scheme for acute renal injury.

The invention belongs to the technical field of experimental animal models, biomedical research and immunology, and discloses a photocoagulation thymus ischemia animal model, a method and application of the photocoagulation thymus ischemia animal model in rapid simulation of thymus degeneration and immune senescence, and the model shows at least one or more characteristics 1-7 days after induction: thymus atrophy, thymus weight or thymus index is significantly reduced; the cortical-medullary structure of thymus is disordered or disappears; the expression distribution of the Keratin 5 / Keratin 8 is abnormal; thymic cell apoptosis is increased, and lipid deposition is enhanced; the proportion of CD4 + CD8 + double positive T cells is reduced, and the proportion of DN2 / DN3 stage T cells is increased; the initial T cell output is reduced; and the immune function is reduced. The pathological mechanism is clear; the modeling period is short, and the immune senescence phenotype can be stably obtained within several days; the injury focus is controllable, and systemic stress or hormone interference is avoided; the model has high repeatability and is suitable for mechanism research and drug screening.

Novel compositions of N-desmethyl ruboxistaurin L-lactate salt and L-lactate salt polymorphs. The use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to modulate GSK-3 signaling is disclosed, as is the use of compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs to inhibit protein kinase C. Methods are also disclosed of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in the treatment of subjects having a neurological disease and / or psychiatric disorder, including Alzheimer's disease, bipolar disorder, depression, schizophrenia, Parkinson's disease, or neuroinflammation, as well as methods of using compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs in treating conditions associated with diabetes mellitus or its complications, or ischemia, inflammation, pulmonary hypertension, congestive heart failure, cardiovascular disease, dermatological disease, or cancer. In addition, compositions of N-desmethyl ruboxistaurin L-lactate salt and polymorphs administered in combination with lithium or other treatments for bipolar disorder are also disclosed.

The present invention relates to the field of stem cell technology and specifically discloses an application of mesenchymal stem cells (MSCs) for the treatment of lower extremity venous ischemia. This application involves pre-treating human mesenchymal stem cells (hMSCs) with the SDF1-FGF2 fusion protein. This pre-treatment significantly enhances the cell viability, blood flow recovery, and anti-inflammatory effects of hMSCs in a lower extremity venous ischemia model. When hMSCs pre-treated with SDF1-FGF2 were injected into mice modeling venous ischemia, they demonstrated superior effects compared to untreated cells in improving blood perfusion, reducing inflammatory responses, and restoring motor function. This method provides a highly effective stem cell therapy strategy for vascular diseases such as lower extremity venous ischemia.

The invention relates to the field of pharmaceutical compositions for promoting atherosclerosis, in particular to a lipid oxide-AGEs composite pharmaceutical composition for promoting atherosclerosis, a method for constructing a rat coronary heart disease ischemia reperfusion injury model by using the composition and application of the composition. The composition comprises 80-90 parts of oxidized lipid, 4-6 parts of 7-ketocholesterol, 2-4 parts of 25-hydroxycholesterol, 8-10 parts of trans-fatty acid, 200-300 parts of an advanced glycosylation end product, 180-220 parts of casein, 320-360 parts of cane sugar, 145-165 parts of corn starch, 45-55 parts of cellulose, 30-40 parts of a mineral mixture, 8-12 parts of a vitamin mixture and 0.4-0.6 mg / kg of folic acid, the vitamin B6 is 1.8 to 2.2 mg / kg, and the vitamin B12 is 0.007 to 0.009 mg / kg.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

The utility model relates to the technical field of electrocardiogram lead wires, in particular to an electrocardiogram lead wire capable of reducing skin damage, which comprises a connector, and the front end and the rear end of the right side of the connector are respectively provided with a limb lead electrode wire and a chest electrode wire. Button type gel electrodes are arranged at the ends, away from the connector, of the limb lead electrode wires and the chest electrode wires, arc-shaped seats are fixedly connected to the outer sides of the limb lead electrode wires, and connecting seats are fixedly connected to the tops of the button type gel electrodes. Under the action of the button type gel electrode, the arc-shaped seat and the elastic capsule, the electrocardiogram lead wire has the advantage of reducing skin damage, and solves the problems that clips are clamped on four limbs, and clips are clamped at the tail ends of the limbs for a long time, so that local skin is easily damaged, even local tissues are ischemic, and the like. And therefore, some patients cannot insist at the end of the examination, the physical fitness of the patients is poor, and the technology is not easy to carry out.

The application discloses a donor perfusion device and a method thereof, and belongs to the field of organ transplantation. The donor perfusion device comprises a control host, a blood storage device, a processing assembly and a pump driving assembly. The blood storage device is used for receiving blood input by a donor. The blood is output to the donor after being processed by the processing assembly. The pump driving assembly is in communication with the blood storage device and the processing assembly respectively, so as to drive the blood to be output after flowing through the processing assembly. The pump driving assembly comprises a first pump body and a second pump body, and the first pump body and the second pump body are respectively in communication connection with the control host. The pump driving assembly has a first working condition and a second working condition. In the first working condition, the control host controls the first pump body to work. In the second working condition, the control host controls the second pump body to work. When the first pump body fails, the second pump body can be started as a backup driving source, so that the driving of blood circulation can be continuously completed, and the ischemia phenomenon of the donor for a long time can be avoided.